GGrantIndex
← Leaderboards

Lisa C Rohan

Magee-Women'S Hospital Of Upmc

Google Scholar ↗PubMed ↗ORCID ↗
$28,808,820
Attributed
$37,042,089
Total exposure
17
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $13.8M · FY2005–25
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$61,960,856 · 18
FDA$298,499 · 1

By mechanism

U19$42,309,392 · 13
UM1$12,781,964 · 1
R61$4,483,403 · 2
R33$2,097,058 · 1
U01$298,499 · 1
P01$289,039 · 1

Top collaborators

Most similar at Magee-Women'S Hospital Of Upmc

Same institution · by research overlap

Others in their field

Top investigators on “Vagina”

Research focus

VaginaPharmaceutical PreparationsSafetyDesignLeadMicrobicideEvaluationBaseDosage FormsAids PreventionClinical ResearchIn VitroTissuesFilmDrug Delivery SystemsProgramsTenofovirCharacteristicsPreventPrototypeClinical TrialsToxic EffectHiv InfectionsAnti-Retroviral Agents

Grant awards (58)

Development of a bioadhesive vaginal film for extended release of MPT antibodies$518,754
R61 · FY2025 · HD · contact PI
Long Acting Film Technology for Contraception and HIV Prevention (LATCH)$1,069,972
R33 · FY2023 · AI · contact PI
Long Acting Film Technology for Contraception and HIV Prevention (LATCH)$1,027,086
R33 · FY2022 · AI · contact PI
Laboratory Center (LC): Microbicide Trials Network$2,058,087
UM1 · FY2021 · AI · contact PI
Long Acting Film Technology for Contraception and HIV Prevention (LATCH)$1,295,960
R61 · FY2021 · AI · contact PI
Long Acting Film Technology for Contraception and HIV Prevention (LATCH)$1,317,796
R61 · FY2020 · AI · contact PI
Laboratory Center (LC): Microbicide Trials Network$691,454
UM1 · FY2020 · AI · contact PI
Laboratory Center (LC): Microbicide Trials Network$5,656,261
UM1 · FY2019 · AI · contact PI
Project-002$3,165,820
U19 · FY2019 · AI
Film Antiretroviral Microbicide Evaluation$2,745,240
U19 · FY2019 · AI
Long Acting Film Technology for Contraception and HIV Prevention (LATCH)$1,350,893
R61 · FY2019 · AI · contact PI
Design Strategies for Film Dosing Forms$879,322
U19 · FY2019 · AI · contact PI
Laboratory Center (LC): Microbicide Trials Network$4,376,162
UM1 · FY2018 · AI · contact PI
Film Antiretroviral Microbicide Evaluation$2,788,873
U19 · FY2018 · AI
Design Strategies for Film Dosing Forms$469,947
U19 · FY2018 · AI · contact PI
Core B: PREVENT Product Development Core$377,806
U19 · FY2018 · AI · contact PI
Film Antiretroviral Microbicide Evaluation$3,662,725
U19 · FY2017 · AI
IND Enabling Critical Path Project$822,732
U19 · FY2017 · AI · contact PI
Design Strategies for Film Dosing Forms$360,852
U19 · FY2017 · AI · contact PI
Core B: PREVENT Product Development Core$243,538
U19 · FY2017 · AI · contact PI
Film Antiretroviral Microbicide Evaluation$4,043,952
U19 · FY2016 · AI
IND Enabling Critical Path Project$1,194,470
U19 · FY2016 · AI · contact PI
Core B: PREVENT Product Development Core$524,449
U19 · FY2016 · AI · contact PI
Design Strategies for Film Dosing Forms$363,426
U19 · FY2016 · AI · contact PI
A Biorelevant Dissolution Methods for Particulate Dosage Forms in the Periodontal Pocket$123,772
U01 · FY2016 · FD · contact PI
A Biorelevant Dissolution Methods for Particulate Dosage Forms in the Periodontal Pocket$49,727
U01 · FY2016 · FD · contact PI
Film Antiretroviral Microbicide Evaluation$4,141,533
U19 · FY2015 · AI
IND Enabling Critical Path Project$1,105,516
U19 · FY2015 · AI · contact PI
Core B: PREVENT Product Development Core$534,969
U19 · FY2015 · AI · contact PI
Design Strategies for Film Dosing Forms$396,320
U19 · FY2015 · AI · contact PI
A Biorelevant Dissolution Methods for Particulate Dosage Forms in the Periodontal Pocket$125,000
U01 · FY2015 · FD · contact PI
Alternative Formulations of Tenofovir and UC781$2,339,108
U19 · FY2014 · AI
Core B: PREVENT Product Development Core$567,556
U19 · FY2014 · AI · contact PI
Dosage Form Design Strategies for Delivery of UC781 and Tenofovir$309,160
U19 · FY2014 · AI · contact PI
Alternative Formulations of Tenofovir and UC781$2,808,029
U19 · FY2013 · AI
Dosage Form Design Strategies for Delivery of UC781 and Tenofovir$284,663
U19 · FY2013 · AI · contact PI
Formulation Development Core$193,893
U19 · FY2013 · AI · contact PI
Alternative Formulations of Tenofovir and UC781$2,687,806
U19 · FY2012 · AI
Formulation Development Core$613,762
U19 · FY2012 · AI · contact PI
Dosage Form Design Strategies for Delivery of UC781 and Tenofovir$430,096
U19 · FY2012 · AI · contact PI
Formulation Core$182,619
U19 · FY2012 · AI · contact PI
Dosage Form Design Strategies for Delivery of UC781 and Tenofovir$399,237
U19 · FY2011 · AI · contact PI
Formulation Development Core$337,201
U19 · FY2011 · AI · contact PI
Formulation Core$207,922
U19 · FY2011 · AI · contact PI
Dosage Form Design Strategies for Delivery of UC781 and Tenofovir$339,622
U19 · FY2010 · AI · contact PI
Formulation Development Core$313,710
U19 · FY2010 · AI · contact PI
Formulation Core$299,967
U19 · FY2010 · AI · contact PI
Formulations$750,994
U19 · FY2009 · AI · contact PI
Formulation Core$331,804
U19 · FY2009 · AI · contact PI
Formulation Development Core$304,706
U19 · FY2009 · AI · contact PI
CORE--FORMULATIONS$194,457
U19 · FY2008 · AI · contact PI
CORE--FORMULATIONS$199,660
U19 · FY2007 · AI · contact PI
CORE--FORMULATIONS$193,478
U19 · FY2006 · AI · contact PI
CORE--FORMULATIONS$198,452
U19 · FY2005 · AI
TRANSPORT AND ACTIVITY OF MICROBICIDES FORMULATIONS$230,705
P01 · FY2002 · AI
Formulation of Combination Microbicides$0
U19 · FY2002 · AI
TRANSPORT AND ACTIVITY OF MICROBICIDES FORMULATIONS$0
P01 · FY2001 · AI
TRANSPORT AND ACTIVITY OF MICROBICIDES FORMULATIONS$58,334
P01 · FY2000 · AI